Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
PURPOSE: AIO KRK-0104 investigated first-line therapy of metastatic colorectal cancer (mCRC) with cetuximab, capecitabine and irinotecan versus cetuximab, capecitabine and oxaliplatin. This analysis investigated the impact of primary tumor location on outcome of patients. PATIENTS AND METHODS: Left-sided primary tumors were defined as tumors from rectum to left flexure, while tumors in the remaining colon were regarded right sided. Overall survival (OS), progression-free survival (PFS) and response rate were correlated with primary tumor location. A Cox regression model was used to evaluate interaction between primary tumor location and KRAS mutation. RESULTS: Of 146 patients of the AIO KRK-0104 trial, 100 patients presented left-sided (of those 68 KRAS codon 12/13 wild-type) and 46 patients right-sided primary tumors (of those 27 KRAS codon 12/13 wild-type). Left-sided tumors were associated with significantly longer OS (p = 0.016, HR = 0.63) and PFS (p = 0.02, HR = 0.67) as compared to right-sided tumors. These effects were present in the KRAS codon 12/13 wild-type population (HR OS: 0.42; HR PFS: 0.54), while no impact of primary tumor location was evident in patients with KRAS codon 12/13 mutant tumors (HR OS: 1.3; HR PFS: 1.01). A significant interaction of KRAS status and primary tumor location concerning OS and PFS was observed. CONCLUSION: Our findings suggest that primary tumor location and KRAS codon 12/13 mutational status interact on the outcome of patients with mCRC receiving cetuximab-based first-line therapy. Left-sided primary tumor location might be a predictor of cetuximab efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 2×
“…to cetuximab or panitumumab treatment (Douillard et al. 2013; Huang et al. 2012; Modest et al. 2012; Douillard et al. 2010; Bokemeyer et al. 2011; amado et al. 2008). this KRAS codon 12/13 wild-type population already excluded about 40 % of all patients and was associated with improved response…”
BackgroundPanitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 9×
“…this population comprises about 50 % of all patients with mCRC with a benefit in median OS following egFR-targeted first-line therapy of 5–7 months (Douillard et al. 2013; Stintzing et al. 2009). taking into account that even RaS wild-type tumors potentially do not define the perfect marker for…”
BackgroundInfluentialVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882 · cited 2×
“However, ORR in clinical trials investigating egFR-based first-line regimens was usually <60 %, indicating that KRAS codon 12/13 wild-type alone was not a sufficient condition to predict response (Douillard et al. 2013; Modest et al. 2012; Van Cutsem et al. 2011; De Roock et al. 2010; Stintzing et al. 2009). the ident…”
BackgroundPeeters, M., Douillard, J.-Y., Van Cutsem, E., Siena, S., Zhang, K., Williams, R., & Wiezorek, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.1492 · Cited by 232 · cited 1×
“…are negative predictive biomarkers and that patients with a KRAS/NRAS mutation do not benefit from an egFR-maBbased therapy (De Roock et al. 2010; Peeters et al. 2013a, b; andre et al. 2013). therefore, mutations of KRAS and NRAS represent an established negative predictor of egFRmaB efficacy.…”
BackgroundHuang, F., Xu, L.-A., & Khambata-Ford, S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1135 · Cited by 33 · cited 2×
“Consequently, only patients with KRAS codon 12/13 wildtype tumors were subjected to cetuximab or panitumumab treatment (Douillard et al. 2013; Huang et al. 2012; Modest et al. 2012; Douillard et al. 2010; Bokemeyer et al. 2011; amado et al. 2008). this KRAS codon 12/13 wild-type population already…”
Background
Cited by
Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3797 · Cited by 709
“Our observations are broadly consistent with previous reports.(5,7-20,24)Active signalingvia theEGFRpathway ismore frequent in patients with left-sided tumors, ostensibly rendering them more responsive to EGFR inhibitor–based therapy.”
BackgroundResultSelf-citationHolch, J. W., Ricard, I., Stintzing, S., Modest, D. P., & Heinemann, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.007 · Cited by 534
Self-citationBrulé, S. Y., Jonker, D. J., Karapetis, C. S., O’Callaghan, C. J., Moore, M. J., Wong, R., Tebbutt, N. C., Underhill, C., Yip, D., Zalcberg, J. R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.015 · Cited by 332
Rectal and colon cancer: Not just a different anatomic site
Tamas, K., Walenkamp, A. M. E., de Vries, E. G. E., van Vugt, M. A. T. M., Beets-Tan, R. G., van Etten, B., de Groot, D. J. A., & Hospers, G. A. P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.06.007 · Cited by 331
Yahagi, M., Okabayashi, K., Hasegawa, H., Tsuruta, M., & Kitagawa, Y. (2016) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-015-3026-6 · Cited by 286
Metadata
- Authors
- von Einem, J. C., Heinemann, V., von Weikersthal, L. F., Vehling-Kaiser, U., Stauch, M., Hass, H. G., Decker, T., Klein, S., Held, S., Jung, A., Kirchner, T., Haas, M., Holch, J., Michl, M., Aubele, P., Boeck, S., Schulz, C., Giessen, C., Stintzing, S., & Modest, D. P.
- Venue
- Journal of Cancer Research and Clinical Oncology
- Published
- 2014-05-10
- Volume
- 140
- Issue
- 9
- Pages
- 1607-1614
- ISSN
- 0084-5353 (ISSN-L)
- 0171-5216
- 1432-1335
- OpenAlex
- W2051550002
- Cited by
- 112
- References
- 5
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. https://app.cochat.ai/papers/10.1007/s00432-014-1678-3
- The paper
- von Einem, J. C., Heinemann, V., von Weikersthal, L. F., Vehling-Kaiser, U., Stauch, M., Hass, H. G., Decker, T., Klein, S., Held, S., Jung, A., Kirchner, T., Haas, M., Holch, J., Michl, M., Aubele, P., Boeck, S., Schulz, C., Giessen, C., Stintzing, S., & Modest, D. P. (2014). Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-014-1678-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.